HAEMONETICS CORPHAEEarnings & Financial Report
NYSE · biomedical engineering
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
NextMay 21, 2026
HAE Q3 2026 Key Financial Metrics
Revenue
$339.0M
Gross Profit
$202.4M
Operating Profit
$67.4M
Net Profit
$44.7M
Gross Margin
59.7%
Operating Margin
19.9%
Net Margin
13.2%
YoY Growth
-2.7%
EPS
$0.95
Financial Flow
HAEMONETICS CORP Q3 2026 Financial Summary
HAEMONETICS CORP reported revenue of $339.0M for Q3 2026, with a net profit of $44.7M (13.2% margin). Cost of goods sold was $136.6M, operating expenses totaled $135.0M.
Key Financial Metrics
| Total Revenue | $339.0M |
|---|---|
| Net Profit | $44.7M |
| Gross Margin | 59.7% |
| Operating Margin | 19.9% |
| Report Period | Q3 2026 |
HAEMONETICS CORP Annual Revenue by Year
HAEMONETICS CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.4B |
| 2024 | $1.3B |
| 2023 | $1.2B |
| 2022 | $953.2M |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $343.3M | $336.2M | $345.5M | $348.5M | $330.6M | $321.4M | $327.3M | $339.0M |
| YoY Growth | 2.1% | 10.4% | 8.6% | 3.7% | -3.7% | -4.4% | -5.3% | -2.7% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.20B | $2.54B | $2.53B | $2.53B | $2.45B | $2.46B | $2.44B | $2.49B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $960.0M | $905.4M | $878.9M | $906.9M | $820.8M | $882.3M | $849.2M | $911.5M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-27.4M | $48.8M | $43.8M | $116.6M | $17.4M | $111.3M | $93.6M |
